Check out these key findings about Nurix Therapeutics Inc. (NRIX)

Nurix Therapeutics Inc. (NASDAQ: NRIX) stock fell -0.23% on Friday to $8.86 against a previous-day closing price of $8.88. With 0.89 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.32 million shares. The 52-week range on NRIX shows that it touched its highest point at $16.81 and its lowest point at $8.12 during that stretch. It currently has a 1-year price target of $27.42. Beta for the stock currently stands at 1.63.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NRIX was down-trending over the past week, with a drop of -6.24%, but this was up by 3.02% over a month. Three-month performance dropped to -20.25% while six-month performance fell -2.64%. The stock lost -45.34% in the past year, while it has lost -19.31% so far this year. A look at the trailing 12-month EPS for NRIX yields -2.97 with Next year EPS estimates of -3.29. For the next quarter, that number is -0.75. This implies an EPS growth rate of -35.80% for this year and -22.80% for next year.

Float and Shares Shorts:

At present, 54.26 million NRIX shares are outstanding with a float of 46.66 million shares on hand for trading. On Aug 30, 2023, short shares totaled 5.58 million, which was 11.57% higher than short shares on Jul 30, 2023. In addition to Dr. Arthur T. Sands M.D., Ph.D. as the firm’s CEO, Pres & Director, Mr. Johannes Van Houte serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 92.75% of NRIX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NRIX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With NRIX analysts setting a high price target of $36.00 and a low target of $12.00, the average target price over the next 12 months is $28.08. Based on these targets, NRIX could surge 306.32% to reach the target high and rise by 35.44% to reach the target low. Reaching the average price target will result in a growth of 216.93% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded NRIX stock several times over the past three months with 6 Buys and 3 Sells. In these transactions, 14,017 shares were bought while 4,549 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 15 over the past year. The total number of shares bought during that period was 40,953 while 13,991 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *